Halozyme Therapeutics Inc (HALO)

[maumar]

I have no idea what that means either.

But what kind of fair value do you come up with on a DCF basis? Just wondering how analysts are coming up with their pretty disparate PTs.

"We value HALO on a DCF basis. We assume risk adjusted credit of 60-80% for Halozyme’s potential ENHANZE royalties from development-stage products over time and some risk-adjusted credit for yet-identified targets/new partnerships. We use a 9% WACC and 0% terminal growth rate."